Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2010-01-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SECONDARY OBJECTIVES
1. To determine whether motor evoked potentials (MEPs) can be elicited from paretic and/or plegic muscles in patients with stroke using navigated TMS (eXimia NBS) and targeting the anatomical cortical areas representing the affected muscles.
2. To determine the correlation between existing MEPs, other TMS parameters and the clinical deficits of limb function.
3. To determine the prognostic value of MEPs and other TMS parameters in predicting motor recovery after stroke
4. To determine the diagnostic value of MEPs and other TMS parameters in monitoring the response to rehabilitation
5. To assess safety by capturing all Serious Adverse Events during both single pulse and rTMS delivery
STUDY PROCEDURES
The purpose of the study including risks and benefits will be explained to potential participants who will then be asked to sign an informed consent form. Potential participants will be screened for inclusion and exclusion criteria
The study will be performed in 2 parts. In part 1 Nexstim eXimia NBS will be utilized for neuronavigation and a third party TMS will be used for delivering the rTMS. In part 2 Nexstim eXimia NBS will be utilized together with Nexstim eXimia TMS for delivering the rTMS. Part 2 will commence once the patients participating in Part 1 have undergone the study visit 22 (see 5.1 below).
15 patients will be recruited to part 1 and 15 patients for part 2 (6 additional subjects will be recruited assuming a 20% drop out rate)
In part 1 of the study 10 subjects will be randomized to rTMS treatment and 5 subjects will be randomized to sham rTMS. Of the 10 rTMS treatment subjects, 5 will be given stimulation protocol A and 5 will be given stimulation protocol B, described below. In part 2, either stimulation protocol A or B will be chosen for continue study based on predetermined outcome criteria. In part 2, 10 subjects will receive this chosen rTMS treatment and 5 subjects will receive sham rTMS.
The study will consist of 24 study visits with the addition of 4 additional visits as needed to complete outcome assessments.
VISIT SCHEDULE
The study will be performed over 24 to 28 sessions:
1. Visit 1(Screening visit): Baseline = 3-9 months after the stroke. The purpose of this visit is to obtain informed consent for the study (if not previously obtained) and to screen subjects for inclusion and exclusion criteria.
2. Visit 2: Baseline assessment. The purpose of this visit is to establish the baseline of injury, motor status and NBS parameters (Hand motor mapping and motor tract integrity, both hemispheres - see appendix A). Subjects will also undergo a structural MRI. The subject will then be randomized to either rTMS or to sham treatment. The baseline visit may if necessary take place on 2 separate days.
3. Visits 3-21: During these visits the patient will undergo standardized task-oriented motor rehabilitation of the hand. In addition the patient will receive the rTMS therapy according to the protocol of the group she/he was randomized into during visit 1. The visits will take place during a 6 week period, three visits per week. During each week the visits will take place each on a separate day and a maximum of two visits will take place on consecutive days. During the first visit of each week (visits 3, 6, 9, 12, 15 and 18) in addition to the rTMS and task-oriented motor rehabilitation, the patient will undergo measurement of NBS parameters (Motor tract integrity, both hemispheres).
4. Visit 22: End of the task-oriented motor rehabilitation. The purpose of the visit is to establish the extent of recovery that has occurred during the rehabilitation. The visit will take place 3-5 days after the last rTMS/rehabilitation session and includes functional motor testing and evaluation of NBS parameters (Hand motor mapping and motor tract integrity, both hemispheres). 1-2 visits may be needed to complete assessment.
5\) Visit 23: 1 month after the end of the rehabilitation therapy. The purpose of the visit is to determine whether any changes in motor function or NBS parameters have occurred within 1 month of ending therapy. The assessment includes functional motor testing and evaluation of NBS parameters (Hand motor mapping and motor tract integrity, both hemispheres). 1-2 visits may be needed to complete assessment.
6\) Visit 24: 6 months after end of the rehabilitation therapy. The purpose of this visit is to determine the long-term rehabilitation success. The assessment includes functional motor testing and evaluation of NBS parameters (Hand motor mapping and motor tract integrity, both hemispheres. In patients experience a new stroke or TIA during this time, only the data prior to the event will be used in the analysis. 1-2 visits may be needed to complete assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active rTMS
Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
Repetititve transcranial magnetic stimulation
1 Hz rTMS to contralesional hemisphere in patients with stroke
Sham rTMS
Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
Repetititve transcranial magnetic stimulation
1 Hz rTMS to contralesional hemisphere in patients with stroke
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetititve transcranial magnetic stimulation
1 Hz rTMS to contralesional hemisphere in patients with stroke
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An ischemic or hemorrhagic stroke suffered 3-9 months prior to the study
* no other known brain abnormalities by history or by structural MRI
* A one-sided stroke resulting in upper extremity paresis
* A Chedoke Arm and Hand Activity Inventory score of 3-6 for the affected limb
Exclusion Criteria
* Pregnant or trying to become pregnant
* History of alcohol abuse, illicit drug use or drug abuse or significant mental illness
* any history of epilepsy
* Any condition that would prevent the subject from giving voluntary informed consent
* An implanted brain stimulator
* Aneurysm clip or other metal in body
* Enrolled or plans to enroll in an interventional trial during this study
* Scalp wounds or infections
* Claustrophobia precluding MRI
* A fixed contraction deformity in the affected limb
* Excessive spasticity as indicated by the Modified Ashworth Spasticity (MAS) Scale \>2/4 in the affected limb
* previous stroke with residual deficits (TIAs not a reason for exclusion)
* premorbid (retrospective) modified Rankin Scale (mRS) score ≥2 of any aetiology
* a concurrent progressive neurologic disorder, acute coronary syndrome, severe heart disease (NYHA Classification \> 3), or other major medical condition
* confirmed or suspected lower-limb fracture preventing mobilization
* patients requiring palliative care
* patients undergoing any other occupational therapy than what is provided in the study
* A recent injection of botulinum toxin to the affected upper limb in the last 3 months, or the need of an injection of botulinum toxin anytime during the study period and follow up
* Ataxia as measured by a score \> 1 on item 7 (limb ataxia) of the NIH stroke scale
* Severe aphasia as measured by a score of \> 2 on item 9 (best language) of the NIH stroke scale
* Severe neglect as measured by a score of 2 on item 11 (extinction and inattention) of the NIH stroke scale
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nexstim Ltd
INDUSTRY
Shirley Ryan AbilityLab
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard Harvey
Medical Director of Stroke Rehabilitation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard L Harvey, MD
Role: PRINCIPAL_INVESTIGATOR
The Rehabilitation Institute of Chicago
Jarmo Laine, MD, PhD, MBA
Role: STUDY_DIRECTOR
Nexstim Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Rehabilitation Institute of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Rehabilitation Institute of Chicago
Nexstim Ltd.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NR-001
Identifier Type: -
Identifier Source: org_study_id